News

Heather Yun, MD, FACP, FIDS who is this year’s IDWeek Chair for the Infectious Diseases Society of America (IDSA) talks about the honor of the position, the collective effort to put together the conference, and offers insights on AMR during war, as well as new emerging infectious disease threats.

The findings may support further COVID-19 vaccination in children and reduce vaccine hesitancy.

A late-breaking abstract presented at IDWeek reports on the data around the Prefusion F Protein vaccine.

The findings emphasize the importance of reviewing all hepatitis B serology reports prior to switching HIV treatment.

Codagenix is reporting data at this year’s IDWeek for its live-attenuated vaccine candidate, CoviLiv.

The algorithm sought to address high rates of false-positive cultures, excessive antibiotic use, and unnecessary diagnostic procedures in an emergency department setting.

The combination antibiotic was equally effective against both monomicrobial and polymicrobial Acinetobacter baumannii-calcoaceticus Complex infections.

The investigational treatment is being developed for this patient population.

Social determinants such as housing and transportation were strong predictors of patients receiving fecal microbiota transplants (FMT).

Adding the oral therapy to standard of care helped reduce total days on oxygen for those hospitalized with COVID-19.

Earlier this year, cases of fungal meningitis were discovered at 2 surgical clinics in Matamoros, Mexico. The CDC offers an update on this deadly outbreak.

A study being presented at IDWeek 2023 demonstrated a 2-fold increase in HIV infections associated with barriers to treatment.

There is a lack of information and teaching going on with this significant, but "silent" organ.

Investigators explored the makeup of antibiotic resistant genes after administration of the live biotherapeutic product, Rebyota (fecal microbiota, Live-jslm), to see what differences would be discovered.

A New Drug Application (NDA) for ceftobiprole was accepted for 3 indications including S aureus bacteremia, days after phase 3 results were published.

Bradley Burnam, CEO of Turn Therapeutics, took his own personal medical experience with a severe skin infection and founded his company to address some of the unmet needs of wound care.

Hikers in Washington State experienced acute gastroenteritis along the Pacific Crest Trail.

In this week's infectious disease news, the Novavax COVID-19 booster gets authorized in the US; Moderna reports topline data on its influenza-COVID-19 combination vaccine; the differences between live biotherapeutic products and conventional FMTs; and the influence of alcohol on hepatitis C treatment.

When implemented broadly, malaria vaccines can have a significant impact on public health.

Behind the scenes, laboratory professionals are processing tests, assays, and other diagnostics to determine data for clinicians to treat patients.

Without regulations for donation practices for conventional fecal microbiota transplants (FMT), clinicians need to consider which therapeutic agents for recurrent C difficile treatment to utilize.

With its Cherokee Nation Hepatitis C Elimination program, they have worked diligently to increase screening and get people into the continuum of care.

The company plans to begin a phase 3 trial for its mRNA-1083 investigational combination vaccine later this year.

The updated emergency user authorization follows similar approvals and authorizations for Moderna and Pfizer's COVID-19 vaccines.

A study highlights that viral infections can accelerate the progression of NAFLD to more severe conditions like non-alcoholic steatohepatitis (NASH) and fibrosis, emphasizing the importance of recognizing these complex relationships.

Screening for Clostridioides difficile in all admissions to ICU identified asymptomatic carriers and their risk for developing and/or transmitting infection.

Check out important news you might have missed including the expanded indication for remdesivir to those with severe hepatic impairment; a small study shows that SARS-CoV-2 infects coronary arteries and increases plaque Inflammation; and some antibiotics are associated with C diff Infection.